Human epidermal growth factor receptor 2 (ERBB2)-targeted therapies such as trastuzumab improve disease-free and overall survival for patients with ERBB2-positive breast cancer (BCA).1 Cardiotoxic effects, characterized by reduced left ventricular ejection fraction (LVEF) or clinical heart failure (HF), are an important treatment-limiting adverse effect of ERBB2-targeted therapy and the most common indication for early trastuzumab interruption.2 Findings from the PHARE and PERSEPHONE trials on the noninferiority of 6- vs 12-month durations of trastuzumab are conflicting, thus the clinical significance of early trastuzumab interruption on BCA outcomes remains uncertain.3,4 Our primary objective was to evaluate the association of early trastuzumab interruption with BCA outcomes in clinical practice.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Copeland-Halperin RS, Al-Sadawi M, Patil S, et al. Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer. JAMA Oncol. 2020;6(12):1971–1972. doi:10.1001/jamaoncol.2020.4749
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: